145 related articles for article (PubMed ID: 31411976)
1. Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers.
Guillamón CF; Gimeno L; Server G; Martínez-Sánchez MV; Escudero JF; López-Cubillana P; Cabezas-Herrera J; Campillo JA; Abellan DJ; Martínez-García J; Martínez-Escribano J; Ferri B; López-Álvarez MR; Moreno-Alarcón C; Moya-Quiles MR; Muro M; Minguela A
Eur Urol Oncol; 2021 Apr; 4(2):246-255. PubMed ID: 31411976
[TBL] [Abstract][Full Text] [Related]
2. NK Cell Education in Tumor Immune Surveillance: DNAM-1/KIR Receptor Ratios as Predictive Biomarkers for Solid Tumor Outcome.
Guillamón CF; Martínez-Sánchez MV; Gimeno L; Mrowiec A; Martínez-García J; Server-Pastor G; Martínez-Escribano J; Torroba A; Ferri B; Abellán D; Campillo JA; Legaz I; López-Álvarez MR; Moya-Quiles MR; Muro M; Minguela A
Cancer Immunol Res; 2018 Dec; 6(12):1537-1547. PubMed ID: 30242020
[TBL] [Abstract][Full Text] [Related]
3. Activating KIRs on Educated NK Cells Support Downregulation of CD226 and Inefficient Tumor Immunosurveillance.
Guillamón CF; Martínez-Sánchez MV; Gimeno L; Campillo JA; Server-Pastor G; Martínez-García J; Martínez-Escribano J; Torroba A; Ferri B; Abellán DJ; Legaz I; López-Álvarez MR; Moya-Quiles MR; Muro M; Minguela A
Cancer Immunol Res; 2019 Aug; 7(8):1307-1317. PubMed ID: 31239317
[TBL] [Abstract][Full Text] [Related]
4. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
5. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
6. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.
Martínez-Sánchez MV; Periago A; Legaz I; Gimeno L; Mrowiec A; Montes-Barqueros NR; Campillo JA; Bolarin JM; Bernardo MV; López-Álvarez MR; González C; García-Garay MC; Muro M; Cabañas-Perianes V; Fuster JL; García-Alonso AM; Moraleda JM; Álvarez-Lopez MR; Minguela A
Oncoimmunology; 2016 Apr; 5(4):e1093721. PubMed ID: 27141379
[TBL] [Abstract][Full Text] [Related]
8. KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells.
Sim MJ; Stowell J; Sergeant R; Altmann DM; Long EO; Boyton RJ
Eur J Immunol; 2016 Jan; 46(1):185-91. PubMed ID: 26467237
[TBL] [Abstract][Full Text] [Related]
9. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
10. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
11. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
Ma P; Sun W
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
[TBL] [Abstract][Full Text] [Related]
12.
Kim K; Byun YJ; Zheng CM; Moon S; Jo SJ; Kang HW; Kim WT; Choi YH; Moon SK; Kim WJ; Piao XM; Yun SJ
Investig Clin Urol; 2024 Jan; 65(1):94-103. PubMed ID: 38197756
[TBL] [Abstract][Full Text] [Related]
13. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
14. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
15. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
16. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer.
Kitamura H; Torigoe T; Honma I; Sato E; Asanuma H; Hirohashi Y; Sato N; Tsukamoto T
Clin Cancer Res; 2006 Aug; 12(15):4641-4. PubMed ID: 16899613
[TBL] [Abstract][Full Text] [Related]
17. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
19. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
de Jong FC; Hoedemaeker RF; Kvikstad V; Mensink JTM; de Jong JJ; Boevé ER; van der Schoot DKE; Zwarthoff EC; Boormans JL; Zuiverloon TCM
J Urol; 2021 Mar; 205(3):701-708. PubMed ID: 33191862
[TBL] [Abstract][Full Text] [Related]
20. Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival.
Beksac K; Beksac M; Dalva K; Karaagaoglu E; Tirnaksiz MB
PLoS One; 2015; 10(7):e0132526. PubMed ID: 26181663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
